Verastem, Inc.

VSTMNASDAQHealthcare● Active

$3.67

$-0.04(-1.08%)

Market Cap$254382017

P/E Ratio—

52W High$11.25

52W Low$3.58

Avg Volume2.3M

Open$3.82

Beta0.27

Free Cash Flow Financials Revenue

Verastem, Inc. (VSTM) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

VSTM · free cash flow · updated Jun 9, 2026

Core FCF metrics

VSTM · FCF · TTM · margin & CAGR

Free cash flow was −$137.5M for FY2025 (fiscal year ending 2025-12-31), down 31.2% year-over-year The FCF margin was -444.8%.

FY2025 Free Cash Flow−$137.5M▼ -31.2% YoY

Trailing 12M (TTM)−$150.9Mtrailing 4 quarters sum

FCF Margin-444.8%−$137.5M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

VSTM · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$137.5M(0M)−$137.5M▼ 31.2%-444.8%

FY2024−$104.8M(0M)−$104.8M▼ 21.2%—

FY2023−$86.5M(0M)−$86.5M▼ 35.8%—

FY2022−$63.7M(0M)−$63.7M▼ 18.6%—

FY2021−$53.5M(0M)−$53.7M▼ 60.1%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

VSTM · P/FCF · FCF yield · FCF per share

Verastem, Inc. (VSTM) reported negative free cash flow of −$0.14B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

VSTM · cash flow statement · operating / investing / financing

For FY2025, Verastem, Inc. generated −$137.5M in operating cash flow and spent 0M in capital expenditures, yielding −$137.5M in free cash flow.

Operating Activities

−$137.5M

Cash from core business operations

2025-12-31

Investing Activities

−$9.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$263.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$137.5M) − |CapEx| (0M) = FCF (−$137.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

VSTM vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Verastem, Inc.YOU

VSTM

−$137.5M-31.2%-444.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Verastem, Inc. (VSTM) reported free cash flow of −$137.5M for FY2025 (fiscal year ending 2025-12-31), down 31.2% year-over-year. The FCF margin was -444.8%.

Verastem, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

VSTM free cash flow · 8 questions

Verastem, Inc. free cash flow was −$137.5M for FY2025, down 31.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$150.9M.

VSTM free cash flowVSTM FCFVSTM FCF 2025VSTM free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Verastem, Inc. · Verastem, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026